Helix BioPharma makes two appointments

Jack Kay as chairman and Professor Kazimierz Roszkowski-Sliz as European Medical Director

Helix BioPharma, a Canadian developer of cancer drugs, has appointed Jack Kay as chairman of the Board. Kay replaces Donald Segal in this capacity, although Segal remains as Helix’s chief executive and a director of the company.

Helix has also hired Professor Kazimierz Roszkowski-Śliż as European Medical Director, to provide critical oversight and direction for Helix’s upcoming European L-DOS47 clinical programme.

Kay has been a director of Helix since 2005. He has worked in the pharmaceutical industry for more than 45 years, and since 1995 has been president of Apotex.

Professor Roszkowski-Śliż is an expert in the field of lung disease and lung cancers, and is a director at the National Tuberculosis and Lung Diseases Research Institute in Warsaw, Poland, where he is also head of the clinical department.

You may also like

Sustainability

Guardtech supporting malaria fight in East Africa with portable 11-bay lab

Suffolk-based experts provide Cleancube Multi 11 for Oxitec’s Friendly mosquito programme in Djibouti
Ingredients

Optimising sample traceability with laser marking technology

Speed and precision in high-throughput tube identification
Ingredients

Flowchem teaching manual now available to download

Guide offers step-by-step instructions for ten reactions including Nobel Prize-winning examples
Analysis

Efficient extraction of proteins from bacterial cells

SoluLyse from Amsbio is a bacterial protein extraction reagent that provides a highly efficient yet gentle method for extracting soluble proteins from bacterial cells
Research & Development

EazeBio and UC Santa Cruz partner to launch instrument-free diagnostic platform for global health

The pair will co-develop a lab-independent cortisol biosensor, delivering rapid, affordable and AI-guided diagnostics for stress, metabolic health and a range of global health applications
Research & Development

Biohm Technologies expands R&D footprint with new microbiome lab in Atlanta

The company has opened a state-of-the-art research lab at Portal Innovations’ Science Square campus in Atlanta, strengthening its microbiome R&D capabilities
Research & Development

Certain medicines accelerate elimination of PFAS from the body, Gothenburg study shows

Researchers at the University of Gothenburg have found that two cholesterol-lowering drugs, cholestyramine and colesevelam, can significantly speed up the removal of harmful PFAS chemicals from the body
Subscribe now